Every material Form 8-K Emergent BioSolutions Inc. has filed with the SEC since October 16, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Emergent BioSolutions received a modification exercising an option period under an existing delivery order, valued at up to $22.3 million, to supply its BioThrax anthrax vaccine to the U.S. Department of War. The filing describes the award as an extension of an existing contract rather than a new financial result, and it does not report revenue, profit, or guidance changes.
Order valued at up to $22.3 million under an existing delivery order and IDIQ contract (W911SR24D0001)
First delivery valued at approximately $7.4 million, beginning this year, with remaining deliveries expected in 2027
Follows an August 2026 contract modification valued at approximately $24 million for CYFENDUS anthrax vaccine to BARDA
Emergent BioSolutions reported third-quarter 2026 total revenues of $110.0 million, down 52% from $231.1 million a year earlier, and a net loss of $32.7 million, compared with net income of $51.2 million in the prior-year quarter. The company lowered its full-year 2026 total revenue forecast to $600 million to $645 million from $645 million to $675 million, and its adjusted EBITDA forecast to $110 million to $140 million from $130 million to $150 million. Chief Financial Officer Rich Lindahl will retire effective December 31, 2026.
Q3 2026 total revenues were $110.0 million versus $231.1 million in Q3 2025; net loss per diluted share was $(0.64) versus $0.91 of net income per diluted share.
2026 total revenue forecast revised to $600 million to $645 million, from $645 million to $675 million previously.
2026 adjusted EBITDA forecast revised to $110 million to $140 million, from $130 million to $150 million previously.
Chief Financial Officer Rich Lindahl retires December 31, 2026; Frank Vargo, Treasurer, becomes interim CFO January 1, 2027.
Emergent BioSolutions said Chief Financial Officer Richard Lindahl will step down as principal financial and accounting officer effective December 31, 2026, and retire on March 31, 2027, after serving as an advisor. Frank Vargo, the company's Vice President and Treasurer, will become Interim Chief Financial Officer on January 1, 2027. The filing reports no financial results, so the change is a leadership transition rather than a change in reported performance.
Richard Lindahl steps down as principal financial and accounting officer effective December 31, 2026, and serves as an advisor until retiring on March 31, 2027.
Frank Vargo, Vice President and Treasurer, becomes Interim Chief Financial Officer on January 1, 2027.
Vargo's interim pay is an additional $3,850 per pay period on top of his base salary of $328,000.
Lindahl will help prepare the Form 10-K for the year ending December 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Emergent BioSolutions Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →